Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
---|
10/23/2003 | US20030199712 Hydrolysis and halogenation of ester of 2-substitued imino-3-methyloxo-butyric acid by photochemical irradiation in one pot using a halogenting agent to form 4-halogeno-2-substituted imino-3-oxo-butyric acid |
10/23/2003 | US20030199701 Treating under hydrolyzing conditions a hydantoin compound to form an alpha-amino acid derivative |
10/23/2003 | US20030199694 Thermally stable trimetrexates and processes for producing the same |
10/23/2003 | US20030199679 Recombinant antibodies specific for TNF-alpha |
10/23/2003 | US20030199673 For inducing immune response and administering immunotherapy |
10/23/2003 | US20030199571 Useful in treatment and prophylaxis of conditions mediated by s-CD23 or tumor necrosis factor; autoimmune disease, inflammation, allergy |
10/23/2003 | US20030199569 Pyrrolidine derivatives |
10/23/2003 | US20030199561 Boronic ester and acid compounds, synthesis and uses |
10/23/2003 | US20030199552 Amide derivatives as NMDA receptor antagonists |
10/23/2003 | US20030199550 Cyclohexane derivatives containing amine or amine oxide, useful for treating hypercholesterolemia and hyperlipemia |
10/23/2003 | US20030199548 Administering quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives containing one of the ring selected from benzene, pyridine, thienyl, furanyl, imidazolyl and triazolyl for therapy in pain management |
10/23/2003 | US20030199541 topical bactericides and disinfectants for surgical instruments; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen; (SML pat indexing merged to app) |
10/23/2003 | US20030199534 Kinase inhibitors |
10/23/2003 | US20030199525 Kinase inhibitors |
10/23/2003 | US20030199521 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
10/23/2003 | US20030199516 Methods of treating infection by drug resistant bacteria |
10/23/2003 | US20030199503 A thiazole-5-carboxylic acid derivatives as viricides, for treating Hepatitis |
10/23/2003 | US20030199502 Indoloquinazolinones |
10/23/2003 | US20030199501 A sulfonylamino-tetrahydro(1,3)thiazolo(5,4-c)pyridinyl or benzothiazole derivatives, for treating diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia |
10/23/2003 | US20030199477 Use of gellable pharmaceutical compositions in periodontology |
10/23/2003 | US20030199474 Administering compounds such as (3,4-dihydroxy-5-(2-hydroxyethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione for inhibiting the invasion and/or metastasis of a carcinoma in a mammal |
10/23/2003 | US20030199473 For therapy of retrovirus infection |
10/23/2003 | US20030199466 For modulating an immune response |
10/23/2003 | US20030199459 Macrolides with antibacterial activity |
10/23/2003 | US20030199103 Novel amino acid sequences for human epidermal growth factor-like polypeptides |
10/23/2003 | US20030199074 Cold-adapted equine influenza viruses |
10/23/2003 | US20030199070 Crystallization of ribosome recycling factor (RRF) and method of developing inhibitor of RRF |
10/23/2003 | US20030199043 Therapeutic proteins (including polypeptide, antibody, peptide or fragment or variants)fused to albumin or fragment or variant linked by a linker peptide; nonglycosylated |
10/23/2003 | US20030198949 Viral polypeptides that regulate or modulate apoptosis |
10/23/2003 | US20030198947 Hepatitis virus sentinel virus I (SVI) |
10/23/2003 | US20030198946 Hepatitis-C virus testing |
10/23/2003 | US20030198941 Method for making an HIV vaccine |
10/23/2003 | US20030198698 Bioactive hexane fraction from Vetiveria zizanioides |
10/23/2003 | US20030198692 Red algae extract; human, veterinary medicine; mixture of cell permeability agent and microbiocide |
10/23/2003 | US20030198691 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
10/23/2003 | US20030198678 Polynucleotide immobilized with block polyether polymer; antibodies against genetic disorders |
10/23/2003 | US20030198650 Equine herpes viruses; hybrid nucleic acid |
10/23/2003 | US20030198647 Rheumatic diseases; autoimmune disease |
10/23/2003 | US20030198644 HCV peptide antigens and methods for the determination of HCV |
10/23/2003 | US20030198643 Adjuvant enhanced immunotherapy |
10/23/2003 | US20030198621 Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
10/23/2003 | US20030198602 Improved absorption; drug delivery |
10/23/2003 | CA2484261A1 Piperidine derivatives having ccr3 antagonism |
10/23/2003 | CA2482395A1 Antiviral therapy on the basis of rna interference |
10/23/2003 | CA2482244A1 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis |
10/23/2003 | CA2482230A1 Polyphosphonate derivatives for toothpaste compositions |
10/23/2003 | CA2481752A1 Composition for modulating a physiological reaction or inducing an immune response |
10/23/2003 | CA2481683A1 Ansamycin formulations and methods for producing and using same |
10/23/2003 | CA2481669A1 Preparation and use of a stable formulation of allosteric effector compounds |
10/23/2003 | CA2481532A1 Imidazole compounds as anti-inflammatory and analgesic agents |
10/23/2003 | CA2481462A1 Heteroclitic analogs and related methods |
10/23/2003 | CA2481320A1 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
10/23/2003 | CA2481207A1 Methods of treatment using ctla-4 antibodies |
10/23/2003 | CA2481186A1 Attenuated gram negative bacteria |
10/23/2003 | CA2481178A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
10/23/2003 | CA2481092A1 Low dose liquid entecavir formulations and use |
10/23/2003 | CA2481087A1 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
10/23/2003 | CA2481042A1 Mycoplasma polypeptides |
10/23/2003 | CA2480415A1 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
10/23/2003 | CA2480410A1 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
10/23/2003 | CA2480217A1 G-type peptides to ameliorate atherosclerosis |
10/23/2003 | CA2479714A1 Branched polyamine steroid derivatives |
10/23/2003 | CA2470016A1 Antibiotic product, use and formulation thereof |
10/23/2003 | CA2466301A1 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
10/23/2003 | CA2448525A1 Nitrogen-containing bicyclic heterocycles for use as antibacterials |
10/22/2003 | EP1355159A1 Use of fragments of carbamyl phosphate synthetase I (CPS 1) for the diagnosis of inflammatory diseases and sepsis |
10/22/2003 | EP1355158A1 Method for diagnosing inflammatory and infectious diseases by detecting the phosphoprotein LASP-1 as inflammation marker |
10/22/2003 | EP1355025A2 Anti-panic opening system for doors |
10/22/2003 | EP1354953A1 Smac-peptides as therapeutics against cancer and autoimmune diseases |
10/22/2003 | EP1354882A1 Dipeptidyl peptidase iv inhibitor |
10/22/2003 | EP1354878A2 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
10/22/2003 | EP1354603A1 Concomitant drugs |
10/22/2003 | EP1354598A2 Therapeutic uses of BR43X2 soluble receptors |
10/22/2003 | EP1354591A1 Topical composition containing agglomerated particles from smoke |
10/22/2003 | EP1354587A1 Medicinal compositions for oral use |
10/22/2003 | EP1354582A2 Emulsion preconcentrates containing cyclosporin or a macrolide |
10/22/2003 | EP1354043A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
10/22/2003 | EP1354042A2 Proteins and nucleic acids encoding same |
10/22/2003 | EP1354039A2 Atp-binding cassette transporter-like molecules and uses thereof |
10/22/2003 | EP1354038A2 Double-stranded rna-mediated gene suppression |
10/22/2003 | EP1354033A2 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
10/22/2003 | EP1353955A2 High affinity antibodies |
10/22/2003 | EP1353942A2 Peptide inhibitors of hiv entry |
10/22/2003 | EP1353929A2 Streptogramin derivatives preparation thereof and compositions containing same |
10/22/2003 | EP1353926A1 Mikanolide derivatives, their preparation and therapeutic uses |
10/22/2003 | EP1353916A2 Pyrazole compounds useful as protein kinase inhibitors |
10/22/2003 | EP1353911A1 Antiviral agents |
10/22/2003 | EP1353907A2 Phosphodiesterase 4 inhibitors |
10/22/2003 | EP1353905A2 Piperidine/piperazine-type inhibitors of p38 kinase |
10/22/2003 | EP1353697A1 Method of preparing biological materials and preparation produced using same |
10/22/2003 | EP1353691A2 Molecular antigen array presenting amyloid beta |
10/22/2003 | EP1353690A2 Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine |
10/22/2003 | EP1353688A2 Method and compositions for immunization with the pseudomonas v antigen |
10/22/2003 | EP1353687A2 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
10/22/2003 | EP1353681A2 Bifidobacteria capable of preventing diarrhea |
10/22/2003 | EP1353679A2 Compositions, methods and apparatuses for singlet oxygen delivery |
10/22/2003 | EP1353672A2 Synthesis of 3-amino-thalidomide and its enantiomers |
10/22/2003 | EP1353664A2 Heterocycle derivatives and methods of use for treating anthrax infection |
10/22/2003 | EP1353651A2 Extended release pharmaceutical compositions containing beta-lactam antibiotics |
10/22/2003 | EP1353647A2 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |